The economic burden of low back pain in KwaZulu-Natal, South 1 Africa: a prevalence-based cost-of-illness analysis from the 2 healthcare provider's perspective. 3

4

*Morris Kahere¹, Cebisile Ngcamphalala², Ellinor Östensson^{,3,4}, Themba Ginindza^{1,2} 5

6

Affiliations: ¹Discipline of Public Health Medicine, School of Nursing and Public Health, 7

8 University of KwaZulu-Natal, Durban, South Africa, ²Cancer & Infectious Diseases

Epidemiology Research Unit (CIDERU), College of Health Sciences, University of 9

KwaZulu-Natal, South Africa, ³Department of Women's and Children's Health, Karolinska 10

Institute, Stockholm, Sweden, ⁴Department of Medical Epidemiology and Biostatistics, 11

Karolinska Institutet, Stockholm, Sweden 12

13

Correspondence author: *Morris Kahere 14

Discipline of Public Health, School of Nursing and Public Health, University of KwaZulu-15

Natal, 2nd Floor George Campbell Building, Mazisi Kunene Road, 4041, Durban, South 16

Africa, Email: mrrskhr@gmail.com 17

18

- Author's email address 19
- 20 Morris Kahere: mrrskhr@gmail.com

21

22

23

24

25

26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 ABSTRACT

28 Background

Globally, low back pain (LBP) is associated with high economic costs due to healthcare expenditure and production loss. There is lack of evidence regarding this in low-and-middleincome-countries (LMICs), including South Africa. Thus, the study aimed to determine the economic burden of LBP from the providers perspective.

33 Methods

We used a retrospective prevalence-based cost-of-illness methodology to estimate the direct medical cost of LBP. Direct medical costs constituted costs associated with healthcare utilisation in inpatient care, outpatient care, investigations, consultations, and cost of auxiliary devices. We used diagnostic-specific data obtained from hospital clinical reports. All identifiable direct medical costs were estimated using a top-down approach for costs associated with healthcare and a bottom-up approach for costs associated with inpatient and outpatient care.

41 **Results**

The prevalence of CLBP was 24.3% (95% CI: 23.5 – 25.1). The total annual average direct 42 medical costs associated with LBP was US\$5.4 million. Acute LBP and CLBP contributed 43 17% (US\$0.92 million) and 83% (US\$4.48 million) of the total annual average direct medical 44 cost, respectively. The per patient total annual average direct medical cost for acute LBP and 45 CLBP were US\$99.43 and US\$1,516.67, respectively. The total average cost of medication per 46 patient for acute and CLBP were US\$82.53 and US\$320.31, respectively. Overall, the 47 outpatient care costs contributed the largest share (38.9%, US\$2.10 million) of the total average 48 direct medical cost, 54.9% (US\$1.15 million) of which was attributed to NSAIDs and only 49 50 10% (US\$0.21 million) of the total outpatient cost was due to rehabilitation. The total average cost of diagnostic investigations was estimated at US\$831,595.40, which formed 15.4% of the 51 52 average total cost.

53 Conclusion

The economic burden of LBP is high in South Africa. Majority of costs were attributed to
CLBP. Action should be taken to develop culturally validated cost-effective prevention
measures to mitigate the burden of LBP.

57 Key words: Chronic low back pain, cost of illness, economic burden, direct medical cost

58

60 Background

Low back pain (LBP) is a global public health problem that occurs in high-income-countries 61 (HICs) and low-and-middle-income countries (LMICs) across all age groups [1]. Despite the 62 technological advancements in diagnosis and the advent of several intervention approaches in 63 the recent years, Low back pain is known to cause significant socio-economic burden to the 64 society [2]. According to the Global Burden of Disease 2017, the years lived with disability 65 (YLD) due to low back pain has increased by 52.7%, from 42.5 million in 1990 to 64.9 million 66 in 2017 [1, 3]. Globally, LBP is now the leading cause of disability [4]. The burden attributed 67 to LBP is predicted to continue increasing, particularly in LMICs where there is limited health 68 coverage and pro-communicable disease control [1]. Great strides should be taken to address 69 this increasing burden and to alleviate the impact it is imposing on health and socio-economic 70 systems. The magnitude of the burden of LBP can be expressed in prevalence, incidence, and 71 cost estimates. 72

The prevalence and incidence estimate of LBP vary among studies due to differences in 73 74 definitions of LBP and methodologies used in different studies over time. Additionally, Anema et al reported that these variations are also influenced by the differences in the healthcare 75 76 seeking behavior, local socio-cultural systems and beliefs around cause and effect [5]. This lack of coherence and homogeneity makes it difficult to compare different studies. However, 77 in the Western world, the point prevalence of low back pain has been reported to be 15-30%, 78 with an estimated 1-month prevalence of 19-43% and a lifetime prevalence of up to 85% [1]. 79 A systematic review by Morris et al investigating the prevalence of low back pain in Africa 80 81 showed a pooled lifetime, 12-months and point prevalence of low back pain of 47%, 57% and 39% respectively [6]. These high prevalence estimates observed in the western world can be 82 attributed to a great awareness of LBP and the willingness to report symptoms as compared to 83 other parts of the world [1, 7]. 84

About 90% of low back pain cases are not severe and normally resolves within a few days to a few weeks but up to 10% of cases will develop chronic low back pain (CLBP). According to Watson et al (2010) most patients do not get completely healed but will have "flare-ups" against a background of CLBP, meaning that the majority of patients will have recurrent symptoms [8]. Regardless of the small percentage of CLBP sufferers, this group is responsible for the majority of the economic burden incurred [9]. A USA study of insurance claims by Hashemi et al showed that up to 8.8% of low back pain sufferers had symptoms that lasted for

a year and accounted for up to 84.7% of the total costs [10]. Similarly, in a study of the UK
working population, only 3% of the patients had symptoms lasted for more than three months
but contributed to 33% of the benefits paid out during the period of that study [8, 11].

A cross-sectional study by Ekman et al investigating the burden of CLBP in Sweden reported 95 that the total annual direct and indirect cost of CLBP per patient were estimated at US\$2 900 96 97 and US\$16 600 in 2002 prices, respectively [9]. Another cross-sectional Switzerland study by Wieser et al reported the direct costs of CLBP to be €2.3 billion and indirect costs were 98 99 estimated at $\notin 4.1$ billion using the human capital approach and $\notin 2.2$ billion using the friction cost method, representing 2.3% of the total gross domestic production[12]. Walker et al 100 estimated the direct cost of LBP at AU\$1.02 billion and indirect cost at AU\$8.15 billion among 101 the Australian adults [13]. In the Netherlands, van Tulder et al reported that the total annual 102 direct costs of LBP were estimated at US\$367.6 million, while the total annual indirect costs 103 were estimated at US\$4.6 billion [14]. Estimates of the economic burden of LBP in the United 104 105 States, for both direct and indirect costs, range from \$84.1 billion to \$624.8 billion [2].

106 The national development plan (NDP) and health policy in South Africa, seek to decrease the prevalence of non-communicable diseases and improve health outcomes. Plans are also 107 underway to implement the national health insurance (NHI) to ensure accessibility to health 108 and promote quality in health. As the leading driver of disability, understanding of the costs 109 associated with CLBP remains critical to inform health care policy decision and subsequently 110 improve management of CLBP. Using patient health records from five hospital this study aims 111 to estimate the economic burden of CLBP among adults (aged \geq 18 years), by estimating direct 112 medical costs including inpatient- and outpatient care for management of LBP in tertiary care. 113

114

115 Materials and Methods

116 Study area

This is a prevalence-based cost of illness study conducted in five randomly selected provincial public hospitals in the eThekwini district in KwaZulu-Natal, South Africa. KwaZulu-Natal is an East coastal province with the second largest population in South Africa. The 2019 population and housing census estimated the population of KwaZulu-Natal to be approximately 11.3 million people (19.2% of the total population) [15]. The KZN GDP per capita is estimated at US\$10 406, which makes it fall in the low-income category [16]

123 Study setting

Addington is a district and regional hospital with 471 beds and 2200 professionals. Addington 124 hospital offer a variety of services including inpatient occupational therapy services for 125 disabled patients. Mahatma Gandhi is a 350 bedded hospital offering inpatient and outpatient 126 care services, including inpatient physiotherapy and occupational therapy services for 127 musculoskeletal patients. Prince Mshiyeni is a 1075 bedded hospital located in Umlazi 128 township. Prince Mshiyeni offers both district and regional services and a variety of clinics 129 available within. Hillcrest hospital is a 167 bedded specialised chronic pain patients' hospital 130 that takes patients who need nursing care. These patients are referred from the hospitals 131 throughout the entire province of KwaZulu-Natal. This hospital also offers outpatient services 132 for chronic medication and rehabilitation. Clairwood is a 275-bedded specialised rehabilitation 133 134 and convalescent hospital.

135 Method of costing


From a healthcare provider's perspective, we employed a prevalence-based method [17] with 136 a bottom-up approach identifying related cost procedures and activities to estimate direct 137 medical costs associated with outpatient and inpatient hospital care for LBP in KZN between 138 2018-2019 [17]. Patient records from five eThekwini District Hospitals were accessed to 139 determine the number of patients diagnosed with LBP. Low back pain diagnoses classified as 140 per the international classification of diseases (ICD)-10 codes, specifically M40 – M54, M96 141 and M99 with subclassification codes related to the lumbar spine or lumbosacral spine were 142 143 included in this study. Codes which did not allow practical delineation of the lumbar spine were excluded [18]. A simple random sampling technique was used to select the participating 144 145 hospitals namely Addington Hospital, Clairwood Hospital, Hillcrest Hospital, Mahatma Gandhi Memorial Hospital and Prince Mshiyeni Memorial Hospital. 146

147

148 Management of LBP in South Africa

The management of LBP in South Africa follows a referral pattern. With the health care system organised into four hierarchical levels of access, the South African primary health care is comprised of primary health care centres (PHC), community health care centres (CHC), local clinics and general practitioners (GP). The PHC is first step in the provision of health care for LBP patients and can only dispense pain medication. Patients requiring further investigations

will be referred to district hospitals where general support in diagnostics (laboratory tests and 154 imaging studies), treatment, care, counselling, and rehabilitation is provided. The treatment of 155 LBP at a district hospital primarily involves prescription of pain medications, mainly non-156 steroidal anti-inflammatory drugs (diclofenac and celecoxib), opioids (tramadol) and 157 antidepressants (amitriptyline) [19]. Tramadol and a combination of tramadol and diclofenac 158 are the most prescribed medication. Antidepressants are prescribed if a patient presents with 159 symptoms of depression, and they can also be used in combination with NSAIDs and or 160 Tramadol. Physiotherapeutic management involves exercises and stretches, transcutaneous 161 electrical nerve stimulation, ultrasound, and laser therapy. Foot orthotics (insoles) are 162 prescribed if the biomechanics of the foot is suspected as the root of the problem. In emergency 163 cases, invasive procedures can be recommended. The flow of events is depicted in Figure 1. 164



165

166 *Fig. 1.* Patient Care Pathway

167 Costs

We collected all identifiable direct medical costs incurred due to consultations, resource utilisations for inpatient and outpatient care events associated with low back pain diagnosis/special investigations and treatment (including medications, any invasive procedures, rehabilitation, use of any auxiliary devices) [20]. We computed all costs at the 2019 price level and converted from the South African Rand (ZAR) to United States Dollar (\$) using the 2019 average exchange rate (US\$1 = ZAR 14.45).

174 Direct medical costs

To estimate the total direct medical costs associated with LBP, we estimated the average cost of each care event documented in the hospital patient records. The average cost for each care component was multiplied by the total corresponding number of patients identified in that component. All cost-generating events were identified and attributed a monetary value based on market or private sources obtained through consultation with senior medical practitioners from private sector (Joint Medical Holdings Ltd).

181

182 **RESULTS**

183 Participants

A total of 12169 files were retrieved. The prevalence of CLBP was 24.3% (2957/12169). Females represented 55.2% (n=6716) and males 44.8% (n=5453) of the study population, Table 1. The mean \pm standard deviation age was 57.6 \pm 15.2 years. Notably, young adults (aged 187 18 – 27 years) represented the smallest percentage of the study population 5.2% (n=636). Whilst a majority of the population were females, the proportion of males were higher in the age category, 58 – 67 (1068 males compared to 1041 females).

190 *Table 1*.

191 Direct medical costs associated with outpatient care of acute low back pain

We performed an age-and-gender stratified costing analysis, Table 2. The estimated average 192 direct medical cost associated with outpatient care for acute low back pain increased with 193 194 increasing age for both genders, Table 2. The total annual average direct medical costs for acute low back pain were estimated at US\$915,948.87 whilst the cost per patient was estimated at 195 196 US\$99.43. The main cost drivers for acute LBP were pain medication consisting of opioids (tramadol) and non-steroidal anti-inflammatory drugs (NSAIDs) mainly diclofenac and 197 198 celecoxib which accounted for 83% (US\$760,294.08) of the total cost, and per patient cost of US\$82.53. NSAIDs, opioids and rehabilitation accounted for 68.5% (US\$626,939.04), 199 200 US\$68.06 per patient, 14.6% (US\$133,355.04), US\$14.48 per patient and 5.4% (US\$49,138.92), US\$5.33 per patient respectively. 201

202 *Table 2*.

203 Direct medical costs associated with chronic low back pain

204 The total annual average direct medical cost for chronic low back pain (CLBP) was estimated at US\$4,48 million with the costs per patient estimated at an annual average cost of 205 US\$1,516.67. The highest average cost per patient was observed among the elderly population 206 in both genders, female (US\$2,219.59) and male (US\$1,932.33), Table 3. As per the cost 207 variables, inpatient care contributed the highest cost constituting 46.31% (US\$2.08 million) of 208 the total annual average costs for CLBP followed by outpatient care 26.5% (US\$1.19 million), 209 investigation 18.5% (US\$ 831,595.40), specialists 7.2% (US\$323,880.63) and auxiliaries 1.4% 210 (US\$62,366.84). The main driver of the outpatient costs for CLBP were medication, which 211 212 contributed 79.6% (US\$ 947,184.96) of the total outpatient costs and 21.12% of the total direct medical cost. NSAIDs were responsible for more than half 55.67 (US\$527,124.00) of the total 213 medication costs and opioids accounted for 24.3% (US\$229,733.28) of the total cost of 214 medication. Males presented with higher costs across the age groups compared female's 215 counterpart (Figure 2). Additionally, the costs increased with age. The total costs among those 216 aged 18-27 were estimated at US\$33,281.37 with the costs more than quadrupling for middle 217 age groups 28 - 37 and 38 - 47 years, *Table 5*. 218

219 *Table 3*.

220 Overall estimated cost for LBP

Overall, the total annual direct medical cost for LBP was estimated at US\$5.4 million with 221 costs for ALBP and CLBP accounting for 17% (US\$0.92 million) and 83% (US\$4.48 million) 222 of the total cost, respectively. The per person annual average total direct cost of ALBP and 223 CLBP was estimated at US\$99.43 and US\$1,516.67 respectively. The average total cost per 224 patient for ALBP and CLBP is shown in Table 6. Outpatient care costs occurred across both 225 ALBP and CLBP recording US\$910,357.74 and US\$1,190,149.62 respectively. Medication 226 costs were comparable for both ALBP (US\$760,294.08) and CLBP (US\$947,184.96). Overall, 227 the main cost driver was outpatient care which contributed 38.9% (US\$2.10 million) of the 228 total direct medical cost (US\$5.4 million). 229

- 230 *Table 4*.
- 231 *Table 5*.
- **232** *Table 6.*
- 233 DISCUSSIONS

From the health care providers' perspective, this study estimated costs of LBP (ALBP and 234 CLBP), in KwaZulu-Natal, South Africa. The estimated total annual direct medical cost of LBP 235 was US\$5.4 million with higher costs for CLBP compared to ALPB. There were more females 236 with ALBP whilst the opposite was observed with CLBP. The argument could be that due to 237 maternal health conditions women are likely to present with ALBP whilst on the other hand 238 this could be reflecting the general health seeking behaviour between females and males. 239 General, evidence on disease pattern and health care seeking behaviour in developing worlds 240 have consistently indicated poor health care seeking behaviour among males compared to 241 242 females [21, 22], hence males being likely to present with CLBP.

The result of this study concurs with several other studies and shows that the economic burden 243 of LBP in South Africa is comparable to other high-income countries. A systematic review by 244 245 Maetzel et al reported that, the small proportion of chronic LBP patients accounts for a large fraction of the total costs [23, 24]. This was also consistent with what was reported by Gore et 246 247 al in their study of the burden of CLBP in the United States [24]. This can be attributed to the fact that acute LBP generally last for a few weeks with little or no intervention. Therefore the 248 cost is mostly associated with pain medication and rehabilitation for a few weeks. Defined by 249 persistent pain and or disability for more the 12 weeks, chronic low back pain is associated 250 with multiple consultations for a long period of time. In some cases special investigations will 251 be required to aid the diagnosis [25]. In line with current evidence, CLBP is associated with 252 significant disability, hence the leading driver of years lived with the disease (YLD) and the 253 sixth in terms of the disability adjusted life years (DALYs) [3, 26, 27], hence more costs. Most 254 studies have focused on developing guidelines for management, thus, there is scarcity of 255 evidence on prevention of LBP [28]. Future research should focus on prevention protocols in 256 order to improve health outcome by mitigating LBP disability and its economic impact. 257

258 Outpatient costs had the highest costs, contributing about 38.9% (US\$2.10 million) of the total costs. This was expected as outpatient care involves multiple visits for both acute and chronic 259 260 LBP. This finding concurs with a study done in Netherlands by van Tulder who reported that 261 the outpatient cost were US\$2.1 million [14]. Expectedly, inpatient care had the second highest cost of US\$2.08 million contributing about 38.5% of the total cost. However, van Tulder et al 262 reported that inpatient costs were higher than outpatient costs. This difference can also be 263 264 attributed to differences in healthcare service delivery, and differences in study methodologies. Inpatient care includes costs for admission and the various professionals a patient interacts with 265 during the hospital stay [29]. The high costs underscores the need for institution measures to 266

sensitize and educate the public about LBP prevention measures to limit cases of admissionwhich comes with increased consumption of medication and significant disability [29].

Outpatient care costs were presented in both ALBP and CLBP. All cases report at the outpatient 269 270 for initial management before referrals for admissions or rehabilitations. It was noted that medication was the main cost driver across all the LBP sub-categories (ALBP and CLBP). The 271 most commonly prescribed medication for LBP was NSAIDs. This finding is consistent with 272 what was observed by Hong et al in their cost of illness study in the UK [30]. Consumption of 273 NSAIDS and opioids was noted to be frequent and indicated by the high costs. Due to the non-274 specific nature of LBP, pain medication is the most common treatment of convenience [25, 31] 275 Interestingly, the costs increased with age. Again, this is because the prevalence of CLBP 276 increases with age and is associated with multiple consultation, and or therapeutic interventions 277 278 [30].

To our knowledge this is a first study to estimate costs of LBP in South Africa. The findings 279 show the direct medical costs associated with LBP in primary care. Low back pain is a 280 condition that has been reported frequently across population and under reported, yet its 281 progress affect quality of life and can lead to loss of income due to disability and subsequently 282 over consumption of medication [25]. Our findings indicate that LBP is of public health 283 concern and should be prioritised as research has shown that the future predictions of its 284 economic burden are substantial and continue to rise in low-and-middle-income-countries if 285 no counteracting strategies are implemented [25]. As such it is imperative that LBP should 286 form part of public health promotion and prevention messaging. 287

Whilst our study is presenting critical information on direct medical costs, we would 288 289 acknowledge that our data was limited to only direct medical costs associated with outpatients, inpatient care, investigations, specialists, and use of auxiliary devices. In addition, results might 290 291 not be representative at a national level because of the limited number of participating hospitals. 292 However, the presented finds still suggest the need for action/attention toward recognizing LBP 293 as one of the public health conditions needing attention and with great potential to have negative consequences on health resources. Secondly, it is likely that the reported numbers 294 295 were underestimated. The ICD codes were handwritten, and this might have affected the reading and results in the exclusion of other potential files, therefore, we it is difficult to exclude 296 selection bias. 297

299 CONCLUSION

The direct medical expenditure for low back pain in KwaZulu-Natal is high mainly as a 300 consequence of inpatient and outpatient care events. Outpatient care was the main cost driver 301 and was significantly contributed by medication. Chronic LBP was responsible for the majority 302 of costs, though it was represented by a small proportion of cases. The main cost drivers for 303 CLBP was the inpatient care which involved ward admissions, nursing care and terminal care. 304 Acute LBP only contributed a small percentage of the total costs, though it was represented by 305 the majority of cases. The most common form of treatment for LBP was pain medication, of 306 which NSAIDs was the most commonly prescribed medication, which was sometimes given 307 in combination with opioids or antidepressants. Cost effective, culturally validated, context 308 specific guidelines for the prevention of LBP should be developed and implemented. Measures 309 310 to be taken to ensure practitioners and patients adherence to guidelines. Thus, this is important for policy makers, funders, stakeholders and other involved actors to consider the 311 312 prioritization of LBP research in the South African context to design cost-effective preventive measures. Urgent action should be taken to develop culturally validated guidelines based on 313 local data to improve the future outcome of LBP and mitigate the burden thereof. 314

315

316 **Declarations**

317 Ethical considerations

The study was approved by University of KwaZulu-Natal Biomedical Research Ethics 318 319 Committee (BREC) (Ref No: BREC/00000205/2019) and the KwaZulu-Natal Department of Health Ethics (Ref No: KZ 201909 002). Gatekeeper permissions were sort from participating 320 institutions prior to the commencement of data collection. To guarantee the anonymity of each 321 participant, the names of respondents, their addresses or other identifying information were 322 included in the questionnaires, but rather each participant was assigned a study ID which was 323 only accessed by the researcher. There was no human participation in this study, as it was a 324 retrospective study of hospital health records for low back pain patients who presented to the 325 hospitals between 2018 and 2019, therefore, no participants consent was required. 326

327 Consent for publication

328 Not applicable

329 Availability of data and materials

All data generated or analysed during this study will be included in the published article.

331 Competing interests

- 332 The authors declare that they have no competing interests.
- 333 Funding

This study was funded by the University of KwaZulu-Natal College of Health Sciences (CHSScholarship).

336 Authors' contributions

MK conceptualised the manuscript, analysed the data, wrote the initial draft, and drew all the tables. MK and CN critically reviewed and improved the first manuscript draft. EO and TG proofread the final manuscript. All authors (MK, CN, EO and TG) approved the final manuscript.

341 Acknowledgements

342 The authors would like to thank the University of KwaZulu-Natal (UKZN) for the provision

of resources towards this project and the UKZN CHS Scholarship that was awarded to facilitate

the research running costs.

345

346

Hartvigsen, J., et al., What low back pain is and why we need to pay attention. The Lancet,

348 **References**

1.

- 350 2018. **391**(10137): p. 2356-2367. 351 2. Dagenais, S., J. Caro, and S. Haldeman, A systematic review of low back pain cost of illness 352 studies in the United States and internationally. The spine journal, 2008. 8(1): p. 8-20. 353 3. Wu, A., et al., Global low back pain prevalence and years lived with disability from 1990 to 354 2017: estimates from the Global Burden of Disease Study 2017. Annals of translational medicine, 2020. 8(6): p. 299-299. 355 356 Vos, T., et al., Global, regional, and national incidence, prevalence, and years lived with 4. 357 disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global 358 Burden of Disease Study 2015. The lancet, 2016. 388(10053): p. 1545-1602. 359 5. Anema, J.R., et al., Can cross country differences in return-to-work after chronic occupational 360 back pain be explained? An exploratory analysis on disability policies in a six country cohort 361 study. Journal of occupational rehabilitation, 2009. 19(4): p. 419. 362 6. Morris, L.D., et al., An update on the prevalence of low back pain in Africa: a systematic 363 review and meta-analyses. BMC Musculoskeletal Disorders, 2018. 19(1): p. 196. Igwesi-Chidobe, C.N., et al., Biopsychosocial factors associated with chronic low back pain 364 7. 365 disability in rural Nigeria: a population-based cross-sectional study. BMJ global health, 2017. 366 **2**(3). 8. Watson, P., C. Main, and G. Waddell, Medically certified work loss, recurrence and costs of 367 368 wage compensation for back pain: A follow-up study of the working population of Jersey. 369 Occupational Health and Industrial Medicine, 1999. 1(40): p. 32. 370 9. Ekman, M., et al., Burden of Illness of Chronic Low Back Pain in Sweden: A Cross-Sectional, 371 Retrospective Study in Primary Care Setting. Spine, 2005. 30(15): p. 1777-1785. 372 10. Hashemi, L., B.S. Webster, and E.A. Clancy, Trends in disability duration and cost of workers' 373 compensation low back pain claims (1988-1996). Journal of Occupational and Environmental 374 Medicine, 1998. 40(12): p. 1110-1119. 375 11. Watson, P., et al., Medically certified work loss, recurrence and costs of wage compensation 376 for back pain: a follow-up study of the working population of Jersey. British Journal of 377 Rheumatology, 1998. 37(1): p. 82-86. 378 Wieser, S., et al., Cost of low back pain in Switzerland in 2005. The European Journal of 12. 379 Health Economics, 2011. 12(5): p. 455-467. 380 13. Walker, B.F., R. Muller, and W.D. Grant, Low Back Pain in Australian Adults: The Economic 381 Burden. Asia Pacific Journal of Public Health, 2003. 15(2): p. 79-87. 382 14. van Tulder, M.W., B.W. Koes, and L.M. Bouter, A cost-of-illness study of back pain in The 383 Netherlands. Pain, 1995. 62(2): p. 233-240. 384 Stats, S., Statistical Release P0302. Mid-year population estimates 2013. Pretoria, 2019: p. 6. 15. 385 Jakovljevic, M. and T.E. Getzen, Growth of global health spending share in low and middle 16. 386 income countries. Frontiers in pharmacology, 2016. 7: p. 21. 387 17. Costa, N., et al., Methodological considerations in cost of illness studies on Alzheimer disease. 388 Health Economics Review, 2012. 2(1): p. 18. 389 Walker, B., R. Muller, and W. Grant, Low back pain in Australian adults: the economic 18. 390 burden. Asia Pacific Journal of Public Health, 2003. 15(2): p. 79-87. 391 Major-Hesloot, M., et al., Management of LBP at primary care level in South Africa: up to 19. 392 standards? African Health Sciences, 2014. 14(3): p. 698-706. 393 20. Rice, D.P., Estimating the cost of illness (health economics series no. 6, PHS no. 947-6). 394 Washington, DC: US Government Printing Office, 1966. 395 21. Galdas, P.M., F. Cheater, and P. Marshall, Men and health help-seeking behaviour: literature
- *review.* Journal of advanced nursing, 2005. **49**(6): p. 616-623.

397	22.	Hjelm, K. and F. Atwine, Health-care seeking behaviour among persons with diabetes in
398		Uganda: an interview study. BMC International Health and Human Rights, 2011. 11(1): p. 11.
399	23.	Maetzel, A. and L. Li, <i>The economic burden of low back pain: a review of studies published</i>
400		between 1996 and 2001. Best Practice & Research Clinical Rheumatology, 2002. 16(1): p. 23-
401		30.
402	24.	Gore, M., et al., The Burden of Chronic Low Back Pain: Clinical Comorbidities, Treatment
403		Patterns, and Health Care Costs in Usual Care Settings. Spine, 2012. 37 (11): p. E668-E677.
404	25.	Hartvigsen, J., et al., What low back pain is and why we need to pay attention. Lancet, 2018.
405		391 (10137): p. 2356-2367.
406	26.	Hoy, D., et al., The global burden of low back pain: estimates from the Global Burden of
407		Disease 2010 study. Annals of the rheumatic diseases, 2014. 73(6): p. 968-974.
408	27.	Murray, C.J., et al., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21
409		regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The
410		lancet, 2012. 380 (9859): p. 2197-2223.
411	28.	Clark, S. and R. Horton, Low back pain: a major global challenge. The Lancet, 2018.
412		391 (10137): p. 2302.
413	29.	Becker, A., et al., Low Back Pain in Primary Care: Costs of Care and Prediction of Future
414		Health Care Utilization. Spine, 2010. 35 (18): p. 1714-1720.
415	30.	Hong, J., et al., Costs associated with treatment of chronic low back pain: an analysis of the
416		UK General Practice Research Database. Spine, 2013. 38 (1): p. 75-82.
417	31.	Buchbinder, R., et al., <i>Low back pain: a call for action</i> . The Lancet, 2018. 391 (10137): p.
418		2384-2388.

Table 1. Demographic characteristics

Age (years)	Female (n = 6716)		Male (n	= 5453)		Overall (N = 12169)			
Mean±SD = 57.6±15.2	(n)	(%)	(n)	(%)	(n)	(%)	95% CI		
18 – 27	387	5,76	249	4.57	636	5.23	4.84 - 5.64		
28 - 37	924	13.76	522	9.57	1446	11.88	11.31 - 12.47		
38 - 47	1797	26,76	1371	25.14	3168	26.03	25,26 - 26,82		
48 - 57	1975	29,41	1675	30,72	3650	29.99	29,18-30,82		
58 – 67	1041	15.50	1068	19.59	2109	17.33	16.66 - 18.02		
68+	592	8.81	568	10.42	1160	9.53	9.02 - 10.07		

Table 2. Costs associated with acute low back pain (n = 9212)

Outpatient care	18 – 27 nt (n = 606)					38 – 47 48 – 57 n = 2502) (n= 2671)		58 – 67 (n = 1354)		≥68 (n = 931)		count pric	Unit price (US\$)	Total price (US\$)	
	F (n = 373)	M (n = 233)	F (n = 799)	M (n = 349)	F (n = 1492)	M (n= 1010)	F (n = 1545)	M (n = 1126)	F (n = 694)	M (n = 660)	F (n = 426)	M (n = 505)	,		
Visits	403	241	999	407	2520	1469	3699	2304	2247	1917	1543	1697	1944 6	5.19	100,924.7 4
Medication														82.5 3	760,294.0 8
NSAIDS	403	241	999	407	2520	1469	3699	2304	2247	1917	1543	1697	1944 6	32.2 4	626,939.0 4
Opioids	178	133	414	173	742	473	711	520	366	365	182	215	4472	29.8 2	133,355.0 4
Rehab	87	61	207	86	393	264	400	299	169	159	105	137	2367	20.7 6	49,138.92
Insoles	22	15	52	23	98	65	91	72	45	40	25	29	577	9.69	5,591.13
Total cost	22,411.5 5	14,398.4 0	54,539.2 5	22,401.1 0	125,558.3 4	75,200.0 2	168,841.3 8	108,650.0 4	98,963.8 2	86,326.0 5	65,603.7 8	73,055.1 4			<u>915,948.8</u> Z
Average cost/patie nt	60.08	61.80	68.26	64.19	84.15	74.46	109.28	96.49	142.60	130.80	154.00	144.66			99.43

Cost variable	Sub- category		- 27 30)		- 37 298)		- 47 666)		- 57 979)		- 67 755)		68 229)	Total count s 2957	Unit price (USS)	Total price (USS)
		F	м	F	М	F	м	F	м	F	M	F	М	<u>2731</u>		
		(n = 14)	(n = 16)	(n = 125)	(n = 173)	(n = 305)	(n = 361)	(n = 430)	(n = 549)	(n = 347)	(n = 408)	(n = 166)	(n = 63)			
Inpatient				,	1.0,	,	,		,	,		100,			(702.3 3)	(2,076,792.2 8)
	Ward	27	38	52	119	398	444	449	822	482	621	383	169	4004	249.00	996,996.00
	ICU			17	36	89	109	207	275	199	308	196	113	1549	116.57	180,566.93
	Nursing care	-			-	93	106	172	181	139	191	73	10	965	899.68	868,191.20
	Terminal care	•	•	•	•	-	-	25	14	59	50	47	•	195	159,17	31,038.15
Outpatient															(402,4 9)	(1,190,149.6
	Total visits	65	49	467	542	1546	1326	2190	2758	2688	3099	1236	384	1635 0	5.19	84,856.50
	Medication														(320.3 I)	(947,184.96)
	NSAIDs	65	49	467	542	1546	1326	2190	2758	2688	3099	1236	384	1635 0	32.24	527,124.00
	Opioids	21	19	191	280	583	667	840	1064	1354	1714	824	147	7704	29.82	229,733.28
	Antidepressa nts	•	•	•	65	585	487	891	1050	1049	1290	472	223	6112	31,14	190,327.68
	Rehabilitatio n	14	37	280	370	699	979	988	1551	758	1222	399	319	7616	20.76	158,108.16
Investigatio ns															(282.2 3)	(831,595.40
	Baseline bloods	4	5	41	58	102	121	142	191	131	151	62	24	1032	150,90	155,728.80
	X-Ray	14	16	123	172	303	359	427	547	348	408	166	61	2944	67.82	199,662.08
	MRI scan	4	4	34	41	109	116	141	180	134	122	80	18	983	484.44	476,204.52
Specialists															(109.5 3)	(323,880,63
	Physician	14	16	119	169	273	328	382	488	302	350	120	10	2571	109,35	281,138.85
	Neurosurgeo n	-	-	3	4	16	21	27	33	26	31	27	27	215	110.73	23,806.95
	Orthopaedic	-	-	4	1	16	13	20	28	19	27	19	24	171	110.73	18,934.83
Auxiliaries															(21.09)	(62,366.84)
	Foot insoles	1	2	10	20	22	35	50	93	50	59	34	22	398	9.69	3,856.62
	Crutches			4		76	71	144	123	102	132	50	6	708	16,26	11,512.08
	Wheelchairs			2	-	16	24	29	58	37	59	25	9	259	181.46	46,998.14
Total cost (S)		15104,2	18177,1 3	89230,2 6	131676, 36	427620, 38	467921, 14	623689, 59	828323, 19	622199, 85	770653, 46	368452, 49	121736, 68			4,484,784,7

Table 3. Costs associated with chronic low back pain (n = 2957)

Average	1,078.8	1,136.0	713.84	761.14	1,402.03	1,296.18	1,450,44	1,508.79	1,793.08	1,888.86	2,219.59	1,932.33	1,516.67
cost	7	7											

Cost variable	Sub-category	Female (n=6716)	Males (n=5453)	Total counts	Unit cost (USS)	Total cost (USS)	Price Source
Inpatient care		· · ·			170.66	(2,076,792.28)	
	Ward	1791	2213	4004	249.00	996,996.00	Private Hospital
	ICU	708	841	1549	116.57	180,566.93	Private Hospital
	Nursing care	477	488	965	899.68	868,191.20	Private Hospital
	Terminal care	131	64	195	159.17	31,038.15	Private Hospital
Outpatient care					172.61	(2,100,507.36)	
-	Total visits	19603	16193	35796	5.19	185,781.24	Market Price
	Medication				140.31	1,707,479.04	
	NSAIDs	19603	16193	35796	32.24	1,154,063.04	Market Price
	Opioids	6406	5770	12176	29,82	363,088.32	Market Price
	Antidepressants	2997	3115	6112	31.14	190,327.68	Market Price
	Rehabilitation	4499	5484	9983	20.76	207,247.08	Market Price
Investigations					68.33	(831,595.40)	
	Baseline bloods	482	550	1032	150.90	155,728.80	Private Hospital
	X-Ray	1381	1563	2944	67.82	199,662.08	Private Hospital
	MRI scan	502	481	983	484.44	476,204.52	Private Hospital
Specialists					26.61	(323,880.63)	-
•	Physician	1210	1361	2571	109.35	281,138.85	Market Price
	Neurosurgeon	121	94	215	110.73	23,806.95	Market Price
	Orthopaedic	102	69	171	110.73	18,934.83	Market Price
Auxiliaries					5.58	(67,957.97)	
	Foot insoles	501	474	975	9.69	9,447.75	Market Price
	Crutches	377	331	708	16.26	11,512.08	Market Price
	Wheelchairs	111	148	259	181.46	46,998.14	Market Price
Total cost		2,687,697.38	2,713,036.26			5,400,733.64	
Average cost		400.19	497.53			443.81	

Table 4. Overall estimated cost low back pain in tertiary care (N = 12169)

Note: average exchange rate for 2019; ZAR14.4496 : USS1.00

	Acute	LBP	CL	BP
Outpatient	n = 9212 ((75.70%)	n = 2957	(24.30%)
	Average total cost	% of Total costs	Average total cost	% of Total costs
Total visits	100,924.74	1.8	84,856.50	1.5
Medication	760,294.08	13.6	920,346.96	16.5
NSAIDs	626,939.04	11.2	527,124.00	9.4
Opioids	133,355.04	2.4	202,895.28	3.6
Antidepressants		-	190,327.68	3.4
Rehabilitation	49,138.92	0.9	158,108.16	2.8
Insoles	5,581.44	0.1	3,856.62	0.1
Total Cost	915,939.54	16.4	1,009,060.08	18.0

Table 5. Outpatient costs comparison between acute and chronic LBP

medRxiv preprint doi: https://doi.org/10.1101/2022.01.19.22269428; this version posted January 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Age	Acute LBP	Chronic LBP
	Annual Per-Patient Average	Annual Per-Patient Average
	Total Cost	Total Cost
18 – 27	60.92	1,107.29
28 – 37	66.23	737.05
38 – 47	79.31	1,349.11
48 – 57	102.89	1,822.25
58 - 67	136.70	1,840.97
68+	149.33	2,072.82
Mean	99.43	1,507.42

Table 6. Per-Patient Average Total Cost for Acute and Chronic LBP

medRxiv preprint doi: https://doi.org/10.1101/2022.01.19.22269428; this version posted January 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .




Figure 1




Figure 2